菜单

Accelerate Clinical Entry with a 6- or 10-Month Timeline

WuXi Biologics offers a DNA-to-IND service that generates the data needed to compile an IND application. From final drug candidate sequence to filing, we transform DNA into a well-characterized product ready for testing in humans. Our integrated, single-source pathway backed by available global capacity advances biologics from concept to clinic.

Built for speed and delivered as 1 program, the service bundles all IND-enabling activities required to reach first-in-human studies.

Cell line development and cell banking

Cell culture and purification process development

Formulation and drug product development

Clinical manufacturing

IND-enabling analysis

Dossier preparation and regulatory support

Fast-Track IND Filing

One Seamless Path to IND Filing

Innovation—not shortcuts—clears the path to IND acceleration. By combining single-sourcing, platform integration, and centralized execution, WuXi Biologics compresses traditional development timelines while preserving program design, data integrity, and regulatory readiness.

Our unified approach supports a full spectrum of modalities—from monoclonal antibodies (mAbs) to complex biologics like bispecifics—and positions your molecule for first-to-clinic advantage.

Single-Sourcing That Simplifies

WuXi Biologics’ single-source model eliminates reliance on third parties by consolidating development, manufacturing, and quality within 1 accountable CRDMO. Our integration removes the fragmentation and vendor handoffs that typically extend IND timelines to a year or more—saving time and resources.

We preserve full program design, including 1 month of stability data, while reducing coordination risks. Our IND delivery is proven at scale.

Over 65 IND projects completed within 6 months

Annual capacity for 200 IND projects programs

More than 600 IND approvals through 2024

A 100% success rate for IND filing

Integrated Platforms and Advanced Methods

Deeply integrated technology platforms and advanced development methods sustain our DNA-to-IND speed. WuXia™ CHO-K1, WuXiUI™, and WuXiUP™ increase expression levels, titers, yields, and overall productivity.

We combine this exclusive technology with high-throughput screening, next-generation sequencing, and other advanced tools to unite all development activities into 1 continuous, end-to-end DNA-to-IND pathway.

Centralized Program Leadership and Communication

To sustain momentum across functions, WuXi Biologics centralizes program leadership under a dedicated project manager and CMC lead. Together, they guide a cross-functional team aligned to a single timeline and shared milestones.

Direct, point-to-point communication between subject matter experts drives rapid issue resolution and keeps programs moving forward without unnecessary delays.

Unified Quality System and Right-First-Time Execution

Quality is embedded throughout our DNA-to-IND service. A single global quality system ensures data integrity, regulatory compliance, and consistency across all activities, reducing program risk while spurring execution.

Right-first-time principles emphasize error prevention over correction, minimizing defects, rework, and operational inefficiencies to deliver.

Faster timelines

Meaningful cost savings

Lower development risk

Uncompromised product quality

CRDMO Industry Veterans

Technical and operational challenges are inevitable. Less common is a partner with the experience to resolve them without disrupting timelines.

With more than 4,300 scientists, including at least 780 with a PhD or equivalent, WuXi Biologics brings deep institutional knowledge to IND acceleration. Our teams have produced over 200 peer-reviewed publications since 2017, reflecting the scientific rigor that enables efficient biologics advancement while maintaining meticulous quality standards.

Proven Acceleration in 2.5 Months

Our CRDMO approach has translated into exceptional speed for real-world programs. In 1 example program, a client engaged WuXi Biologics to urgently advance a COVID-19-neutralizing mAb from DNA to IND. WuXi Biologics completed the program in only 2.5 months while preserving product quality and safety.

Although the pandemic has passed, the innovations developed during the COVID-19 era established a robust framework that now supports an industry-leading 6-month DNA-to-IND timeline. Enduring technologies and methods continue to reduce timelines across a broad range of biologic programs.

Read a publication demonstrating IND acceleration

The Market Is Waiting

WuXi Biologics reduces complexity and de-risks one of the most challenging stages of biologic development. Delivered as a cross-functional, contractable lifecycle service, DNA-to-IND aligns your molecule to critical regulatory milestones with equal parts speed and assurance. DNA-to-IND readily integrates with WuXi Biologics other lifecycle services: target-to-lead and IND-to-BLA. This modularity enables engagement at any stage while preserving alignment across a global CRDMO solution. What Stage Is Your Molecule At?
Contact Us to Discuss